Director, Nonclinical Due Diligence & External Innovation

Darum lohnt es sich

The role ensures integrated, objective, and decision‑relevant evaluations of nonclinical pharmacology, PK/QSP, and toxicology data to identify development risks, data gaps, and mitigation strategies and to inform portfolio decisions. /p pThe incumbent will further act as nonclinical representative for selected Research programs and support oversight of nonclinical strategies and programs across all Therapeutic Areas. /p pThe role reports to the Executive Director, Head of Nonclinical Development. /p h3Responsibilities and accountabilities /h3 ul liLeads operational execution of nonclinical due diligence for assigned opportunities. /li liActs as hands‑on scientific integrator, translating expert input into clear risk narratives. /li liTrusted subject‑matter lead for nonclinical DD on individual deals. /li liLead end-to-end nonclinical due diligence for individual assets or transactions, from request through final governance readout. /li liIntegrate input from Toxicology, PK/QSP, Nonclinical Pharmacology, and external experts into a single, coherent scientific assessment. /li liIdentify FIH‑enabling gaps, translational risks, and regulatory limitations, with clear mitigation proposals. /li liPrepare high‑quality DD reports, executive summaries, and risk tables for governance review. /li liAct as NCD scientific interface to Business Development and Therapeutic Area teams at the project level. /li liContribute to maintenance and continuous improvement of nonclinical DD frameworks and templates. /li liMentor junior contributors and matrix team members as appropriate. /li liEscalates complex or high‑impact issues to Head of NCD /li liChair of “NCD Review Committee” /li /ul h3Qualifications: /h3 h3Education: /h3 ul liAdvanced degree (Ph.D., D.V.M., or equivalent) in toxicology, pharmacology, or a related field /li liToxicology training, board certification preferred /li /ul h3Experience : /h3 ul liExperience in nonclinical development (10+ years) with proven experience in due diligence or external innovation, ideally across various geographies. /li liStrong understanding of FIH‑enabling nonclinical requirements, particularly for biologics and complex modalities. /li liAbility to communicate complex scientific risk clearly to non‑expert stakeholders. /li liExperience across multiple therapeutic areas and modalities is highly desirable. /li liProven ability to work effectively both independently or in a team setting, and to meet set goals by managing own timelines. /li liExperience in working in cross-functional, multicultural and international teams. /li liExcellent communication and analytical skills. /li liExperience in analyzing and presenting research results to scientific and professional audiences. /li liStrong planning and organizational skills. /li liAbility to work successfully in a matrix organizational structure. /li liStrong negotiation skills and ability to identify and engage internal and external expertise as needed. /li liGood understanding of drug development process, strong knowledge of ICH/GLP /li liFluent in English, oral and written; /li /ul pThe role requires onsite presence 3 days per week. /p pThe role can be based in Zurich, Switzerland or Waltham, USA. /p /p #J-18808-Ljbffr ppThe Director Non-Clinical Due Diligence External Evaluations provides scientific leadership for nonclinical due diligence supporting CSL’s in‑licensing, acquisitions, and strategic collaborations.